Hyperbaric Oxygen Therapy (HBOT)

Verdict: Mixed (small striking trial / no replication / commercial entanglements) Last reviewed: 2026-04-25 Triangulated against anchor: NMN (Suggestive) — HBOT sits in that vicinity

TL;DR

Efrati group (Aviv Clinics, Israel) published a 2020 trial showing HBOT increased peripheral blood telomere length and reduced senescent T-cell markers in 35 older adults — striking, biomarker-only, single-group, commercially-affiliated. Independent replication has not materialized at scale. Standard medical HBOT for established indications (decompression sickness, certain wound types, CO poisoning) is well-established; the aging application rests on one group's biomarker work. Verdict: Mixed — interesting biology, decisive replication missing, substantial commercial entanglement.

What it is

Breathing 100% oxygen at supra-atmospheric pressures (typically 1.5-2.5 ATA / atmospheres absolute). Established medical indications: decompression sickness, gas embolism, severe CO poisoning, certain non-healing diabetic wounds, radiation tissue injury. "Aging" protocol per Efrati: 60 sessions, 90 minutes each, 5 days/week × 3 months — substantial time and cost commitment.

Proposed mechanism

• Hyperoxia paradox: intermittent high oxygen exposure → relative-hypoxia signaling on return to normoxia → induction of HIF-1α, VEGF, angiogenesis, mitochondrial biogenesis
• Possible telomerase activation (mechanism for the telomere-length finding)
• Stem cell mobilization
• Anti-inflammatory effects via various pathways

Confidence: Established for the hyperoxia-paradox cellular mechanisms; Plausible for aging-relevant translation; Hypothetical for clinically meaningful longevity benefit.

Evidence ladder

Animal models (T4)

Healthspan signals in disease models. ITP not tested. Lifespan effects not central in animal aging research; the field is human-trial-led.

Human (T2)

• Hachmo / Efrati 2020 (Aging journal) — 35 healthy older adults, 60 sessions HBOT, peripheral blood biomarkers. Telomere length increased ~20-38% across cell types; senescent T-cell markers decreased significantly. Single-arm, no placebo, single-site, single-group.
• Subsequent Efrati group publications on cognition, fibromyalgia, and other indications — generally positive, generally from the same group.
• Independent replications: Notably absent at scale. Methodology section 6 requires multi-lab replication.
• Aviv Clinics (Efrati-affiliated) commercialize the aging protocol at substantial cost.
• No mortality or hard-endpoint longevity RCT.

Confounds

• Single-group dominance — Efrati group + Aviv Clinics is the dominant evidence source, with substantial commercial entanglement.
• Telomere measurement methodology — flow-FISH and other telomere measurements have non-trivial inter-lab variability; the magnitude of effect (20-38%) in 3 months is biologically surprising and warrants independent confirmation.
• No placebo in the Hachmo 2020 trial — sham HBOT (low-pressure or air-only) is methodologically possible but wasn't done.
• Selection / volunteer effects in self-paying clinical populations.

Conflict of interest scan

• Substantial COI: Efrati is medical director of Aviv Clinics, which commercializes the protocol. Apply at least 1-tier discount per methodology, possibly more given the lack of pre-registration of the original aging trial.
• The clinical research is plausibly genuine; the framing in popular media is heavily commercially driven.

Human translation

Honest read: HBOT for accepted medical indications is FDA-approved and works. The aging claim rests on one group's striking but methodologically limited biomarker findings, with substantial commercial layering and no independent replication. The protocol is expensive ($10,000-30,000 for a course at clinics), time-intensive, and the underlying evidence base is much thinner than the marketing implies.

For decompression sickness, severe wounds, or CO poisoning: HBOT is established. For "longevity": the case is genuinely speculative.

Calibrated verdict

Mixed. Per methodology section 3, Mixed is "tier-appropriate evidence exists but replication has failed or sex/strain dependence is severe." For HBOT, the issue is missing replication rather than failed — but the single-group dominance plus commercial entanglement plus surprising effect magnitude warrants caution. Sits below NMN (Suggestive) given the COI and replication gap.

Confidence interval on verdict

• Could move to Probable with independent multi-lab replication of the telomere / senescent-cell findings, ideally with placebo control. None imminent.
• Could move to Mostly hype if independent replication fails or the original methodology is shown to be artifact-prone.
• Most likely 2-year trajectory: stable; commercial market continues regardless.

Open questions

• Q: Has any independent group attempted to replicate the Hachmo 2020 telomere findings with placebo control?
• Q: What is the dose-response — do shorter / less intensive HBOT protocols produce proportional biomarker effects?
• Q: Are there safety signals (oxidative stress, retinal effects, ear barotrauma) at the aging-protocol doses that haven't surfaced in shorter courses?

Sources

• Hachmo et al. 2020, Aging — HBOT increases telomere length and decreases immunosenescence in isolated blood cells
• Frontiers in Aging 2024 — HBOT future prospects in regenerative and anti-aging therapy

Produced under methodology locked 2026-04-24. Triangulated with caveats on single-group dominance + COI.